|

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

RECRUITINGSponsored by Hunan Province Tumor Hospital
Actively Recruiting
SponsorHunan Province Tumor Hospital
Started2020-03-24
Est. completion2024-12-24
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT04324125

Summary

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Eligibility

Age: 18 Years+
Inclusion Criteria:

* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
* HER 2 Insertion or Amplification
* First Diagnosis and Treatment
* Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody

Exclusion Criteria:

* Patients received antitumor treatment before
* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.